Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
Results from an open label clinical study, evaluating an oral daily dose of the drug enobosarm, shows promise for women with metastatic, androgen receptor positive, estrogen receptor positive breast cancer.
The new data is from a phase 2 study to be reported on Monday, June 2, 2014 at the meeting in Chicago of the American Society of Clinical Oncology (ASCO) by Beth Overmoyer, MD, director of the Inflammatory Breast Cancer Program at the Susan F. Smith Center for Women’s Cancers at Dana-Farber Cancer Institute.
“We are very encouraged by our findings,” said Overmoyer. “This drug is tissue specific, so many of the side effects normally experienced by patients on endocrine therapy did not occur. We only encountered rare nausea and minimal muscle aches.”
Enobosarm is an oral, nonsteroidal selective androgen receptor modulator (SARM) that has been developed for its selective androgenic activity with minimal side effects. More than 80% of estrogen receptor positive metastatic breast cancer is androgen receptor positive, supporting the development of targeted therapy for the androgen receptor in this patient population.
In addition to treating metastatic breast cancer, enobosarm is also being tested to benefit the prevention and treatment of a wide variety of muscle wasting conditions and other cancers.
This study was supported in part by GTx, Inc. who provided drug and clinical trial support.
For more information about Dana-Farber research being presented at ASCO, visit www.dana-farber.org/asco.